Skip to content

Effects of Early Exercise Rehabilitation in Severe Burns

Pathophysiological Mechanisms and Early Exercise Rehabilitation Counter Measures of Hypermetabolism and Muscle Wasting in Severe Burns.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04372550
Enrollment
90
Registered
2020-05-04
Start date
2019-11-25
Completion date
2021-10-31
Last updated
2020-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burns

Keywords

Burns, Exercise rehabilitation, Exercise Therapy, Muscle wasting, Hypermetabolism, Insulin resistance

Brief summary

BACKGROUND: Postburn changes in glucose and protein metabolism are at their peak during the acute phase of severe burns. The resulting metabolic derangements lead to substantial muscle wasting, insulin resistance, which ultimately hampers full recovery and reintegration into society. PURPOSE: This randomized controlled trial was initiated to investigate the effects of exercise-based rehabilitation on muscle wasting, insulin resistance, and quality of life during the acute phase of severe adult burns. METHODS: Severly burned adults (40-80%TBSA) will be recruited from one of China's largest burn centres. Subjects allocated to the intervention group will undergo a 6-12 week long exercise program in addition to standard care rehabilitation. As part of the exercise program, participants will carry out progressive resistance and aerobic training, initiated as soon as medical safety and patient cooperation allow. Exercise type and dosage will be chosen according to patient status in terms of grafts, mobility, and strength. The control group will receive standard care rehabilitation only, including passive, assisted, active range of motion exercise, functional exercise, and scar treatment. The results of this translational research will provide insight into the effects and mechanisms of exercise on both a fundamental and clinical spectrum.

Detailed description

The added exercise intervention is initiated in line with the following readiness criteria, which were checked prior to each training session: Criteria: * Cardiorespiratory stability: * Mean arterial pressure (MAP) 60 - 110 mmHg * fraction of inspired oxygen (FiO2) \<60% * partial pressure of oxygen / fraction of inspired oxygen (PaO2/FiO2) \>200 * Respiratory rate \<40 bpm * Positive end expiratory pressure (PEEP) \<10 cmH2O * no high inotropic doses (Dopamine \>10 mcg/kg/min or Nor/adrenaline \<0,1 mcg/kg/min) * Temp. 36 - 38,5°C * Richmond Agitation Sedation Scale (RASS) -2 - +2 * Medical Doctor clearance * Medical research council (MRC) score lower limbs ≥3 Accordingly, the post burn starting time differs per enrolled subject. Exercises are administered as in-bed exercises or out-of-bed exercises, depending on whether subjects are able and allowed to engage in out-of-bed mobility. Exercise intensity for resistance training is set at 60% peak force based on a weekly peak force measurement by hand-held dynamometry, or on a 3 RM in case of out of bed exercises. Aerobic exercise intensity is set at 50-75% peak Watts determined by a weekly cycle ergometer or treadmill ramp protocol.

Interventions

OTHERExercise

Resistance and aerobic exercise in addition to standard of care rehabilitation

OTHERStandard of Care

Standard of care rehabilitation

Sponsors

Research Foundation Flanders
CollaboratorOTHER
Wuhan Third Hospital
CollaboratorOTHER
Universiteit Antwerpen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

Analysis of the primary outcome is carried out blind.

Intervention model description

Randomized Controlled Trial

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* ≥40 - ≤70 %TBSA * Burn depth: 2nd deep / 3rd degree

Exclusion criteria

* Electrical burn (except flash burns) * Associated injury: fracture lower limb * Diabetes Mellitus type 1 * Central neurological/neuromuscular disorders (interfering with assessment/exercise) * Cognitive / psychological disorders (interfering with cooperation) * Cardiopulmonary disease (interfering with exercise safety) * Pregnancy * Palliative care

Design outcomes

Primary

MeasureTime frameDescription
Change in quadriceps muscle layer thickness (QMLT)Baseline - 12 weeksMethod: B-mode ultrasound on the anterior aspect of the thigh. Technique: maximal and minimal pressure Location: measured at 1/2 and 2/3 of the distance between anterior superior iliac spine and the superior pole of the patella. Analysis: An average of 3 trials will be recorded and analyzed using dedicated software
Change in rectus femoris cross sectional area (RF-CSA)Baseline - 12 weeksMethod: B-mode ultrasound on the anterior aspect of the thigh. Technique: minimal pressure. Location: measured at the most proximal distance where the entire muscle belly is still visible on the ultrasound image. Analysis: An average of 3 trials will be recorded and analyzed using dedicated software.

Secondary

MeasureTime frameDescription
Change in insulin resistanceBaseline and 12 weeksMethod: HOMA-2 calculated by fasting plasma glucose and insulin, analysed by Western Blot Chemiluminescence

Other

MeasureTime frameDescription
Change in C-reactive proteinBaseline and 12 weeksWestern Blot Chemiluminescence
Change in Insulin like growth factor 1 (IGF-1)Baseline and 12 weeksWestern Blot Chemiluminescence
Change in GlucagonBaseline and 12 weeksELISA kits DGCG0, R&D Systems, Inc, USA
Change in MyostatinBaseline and 12 weeksELISA kits DGDF80, R&D Systems, Inc, USA
Change in isometric peak force (knee extension)Baseline and 12 weeksMethod: Hand-held dynamometry (Lafayette instrument Co. Europe, U.K.). Isometric peak fore is measured by a 'make' manoeuvre with a fixation band disallowing movement. Test position: Supine with a fixation band fixed to the hospital bed. Analysis: Best of 3 trials
Change in Interleukin-1Baseline and 12 weeksWestern Blot Chemiluminescence
Change in isometric peak force (hip extension)Baseline and 12 weeksMethod: Hand-held dynamometry (Lafayette instrument Co. Europe, U.K.). Isometric peak fore is measured by a 'make' manoeuvre with a fixation band disallowing movement. Test position: Supine with a fixation band fixed to the hospital bed. Analysis: Best of 3 trials
Change in hand grip strengthBaseline and 12 weeksMethod: Baseline LITE hydraulic dynamometer Analysis: Best of 3 trials
Change in Burn Specific Health Scale-Brief (BSHS-B)Baseline and 12 weeksBurn-specific quality of life, measured by the Burn Specific Health Scale-Brief questionnaire (Mandarin Chinese version). Total score 152 (0 worst score, 152 best score), consisting of 6 subdomains: 1\) Body imagine (36 points) Simple abilities (36 points) Sexuality (24 points) Affect (32 points) Work (16 points) Interpersonal relationship (8 points)
Change in EQ-5D-5LBaseline and 12 weeksOverall quality of life, measured by EQ-5D-5L (Mandarin Chinese version) Total score: 25 points (0 worst score, 25 best score), consisting of 5 subdomains 1. Mobility (5 points) 2. Self-care (5 points) 3. Usual activities (5 points) 4. pain / discomfort (5 points) 5. Anxiety / Depression (5 points) EQ overall health assessed on a Visual Analogue Scale, Total 0-100 (0 worst, 100 best score)
Number of adverse eventsBaseline and 12 weeksRecording of complications during exercise: Graft take, Wound infections, Medical, Cardio-respiratory safety
Change in isometric peak force (hip flexion)Baseline and 12 weeksMethod: Hand-held dynamometry (Lafayette instrument Co. Europe, U.K.). Isometric peak fore is measured by a 'make' manoeuvre with a fixation band disallowing movement. Test position: Supine with a fixation band fixed to the hospital bed. Analysis: Best of 3 trials
Change in Interleukin-6Baseline and 12 weeksWestern Blot Chemiluminescence
Change in Tumor Necrosis Factor alpha (TNF-α)Baseline and 12 weeksWestern Blot Chemiluminescence

Countries

China

Contacts

Primary ContactDavid R Schieffelers
david.schieffelers@uantwerp.be+32465419848

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026